Pfizer Inc. (NYSE:PFE) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 74.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,066,501 shares of the biopharmaceutical company’s stock after purchasing an additional 4,736,500 shares during the period. Pfizer accounts for about 1.1% of Two Sigma Advisers LP’s portfolio, making the stock its 13th largest holding. Two Sigma Advisers LP owned approximately 0.20% of Pfizer worth $361,875,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Hudson Bay Capital Management LP boosted its holdings in shares of Pfizer by 2.2% during the 2nd quarter. Hudson Bay Capital Management LP now owns 230,000 shares of the biopharmaceutical company’s stock worth $7,521,000 after purchasing an additional 5,000 shares during the last quarter. Argus Investors Counsel Inc. lifted its holdings in Pfizer by 5.3% in the second quarter. Argus Investors Counsel Inc. now owns 108,480 shares of the biopharmaceutical company’s stock valued at $3,547,000 after acquiring an additional 5,500 shares during the last quarter. AE Wealth Management LLC lifted its holdings in Pfizer by 35.0% in the second quarter. AE Wealth Management LLC now owns 376,967 shares of the biopharmaceutical company’s stock valued at $12,327,000 after acquiring an additional 97,799 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its holdings in Pfizer by 21.2% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 15,704 shares of the biopharmaceutical company’s stock valued at $514,000 after acquiring an additional 2,744 shares during the last quarter. Finally, Bank of Nova Scotia Trust Co. lifted its holdings in Pfizer by 6.1% in the second quarter. Bank of Nova Scotia Trust Co. now owns 80,342 shares of the biopharmaceutical company’s stock valued at $2,627,000 after acquiring an additional 4,591 shares during the last quarter. Institutional investors and hedge funds own 69.08% of the company’s stock.

A number of research analysts recently commented on PFE shares. TheStreet upgraded Pfizer from a “c+” rating to a “b” rating in a report on Monday, June 1st. UBS Group upped their price objective on Pfizer from $37.00 to $39.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Piper Sandler boosted their target price on Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. JPMorgan Chase & Co. cut their target price on Pfizer from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, June 1st. Finally, Mizuho reissued a “buy” rating and issued a $43.00 target price on shares of Pfizer in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $39.61.

Shares of Pfizer stock traded down $0.18 during trading hours on Wednesday, reaching $36.78. 20,864,053 shares of the company were exchanged, compared to its average volume of 29,439,164. Pfizer Inc. has a 1 year low of $27.88 and a 1 year high of $40.97. The stock’s fifty day moving average is $37.77 and its 200 day moving average is $35.70. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.42. The firm has a market cap of $204.38 billion, a PE ratio of 14.60, a PEG ratio of 2.91 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.14. The business had revenue of $11.80 billion for the quarter, compared to analyst estimates of $11.55 billion. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The company’s revenue was down 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.80 earnings per share. Research analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Friday, July 31st were issued a $0.38 dividend. This represents a $1.52 annualized dividend and a yield of 4.13%. The ex-dividend date of this dividend was Thursday, July 30th. Pfizer’s dividend payout ratio (DPR) is presently 51.53%.

In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were purchased at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the acquisition, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $154,200. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.08% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Most Volatile Stocks

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply